Alumis inc ALMS.US 總覽分析
ALMS 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
ALMS 近期報酬表現
-5.45%
Alumis inc
0.38%
同產業平均
-0.07%
S&P500
與 ALMS 同產業的標的表現
- TCRT Alaunos therapeutics inc價值 2 分趨勢 5 分波段 3 分籌碼 1 分股利 1 分查看更多
ALMS 公司資訊
Alumis Inc. is a clinical-stage biopharmaceutical company. The Company is developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases. It builds a pipeline of molecules with the potential to address a range of immune-mediated diseases, such as monotherapy or combination therapies. It is focused on developing its two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that it is developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. Its ESK-001 is an oral, highly selective, small molecule, allosteric inhibitor of tyrosine kinase 2 that is being evaluated for the treatment of patients with moderate-to-severe plaque psoriasis and systemic lupus erythematosus. A-005, a CNS-penetrant, allosteric TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases.